DarioHealth presented four studies at the American Diabetes Association’s Scientific Sessions in June 2026, demonstrating measurable clinical and economic improvements in high-risk cardiometabolic populations using its digital health platform.
Clinical and Weight Outcomes
The studies tracked outcomes across participants with diabetes, hypertension, and obesity. When participants were compared with control groups, they experienced 0.23 fewer hospitalizations per patient per year, with similar improvements associated with estimated payer savings of approximately $5,077 per participant per year. For weight management, Dario’s digital health intervention alone delivered 6.4% weight loss at 12 months, while combining Dario with GLP-1 therapy produced 14.3% weight loss. Among high-risk diabetes users, 44.8% achieved at least a 1% eA1c reduction at 12 months.
Platform Strategy and Enterprise Value
The four presentations underscore Dario’s platform approach to cardiometabolic care, which integrates an AI-driven engagement engine, connected devices, and personalized human coaching. The company’s core finding is that sustained engagement on a single cardiometabolic platform can produce measurable clinical improvement across overlapping chronic conditions while reducing avoidable utilization and the cost of managing multiple point solutions. Consistent engagement predicted both weight loss and glycemic improvement.
The research reinforces Dario’s strategic growth phase, positioning the company to move closer to care and participate in the medical spend associated with clinical outcomes. The growing body of data—including 27 studies presented at the ADA alone over the past eight years—supports the company’s enterprise thesis for payers, employers, and other buyers seeking lower costs and stronger member retention.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/dario-presents-four-studies-at-american-diabetes-association-scientific-sessions-highlighting-commercial-and-clinical-value-of-its-digital-health-platform-302793052.html